Search Results 821-830 of 24276 for In situ

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - Mayo Clinic

    ... in situ cervical cancer; adequately treated stage I or II cancer from which the patient is currently in complete remission; any other cancer from which the ...

  2. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy - Mayo Clinic

    As pazopanib is well tolerated with minimal side effects, the investigators propose a phase II study to evaluate pazopanib as a first-line agent in ... in situ of ...

  3. Publications - Jess F. Peterson, M.D. - Mayo Clinic

    Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer J. 2019 Dec 16; 9 (12): ...

  4. Breast cancer - Doctors and departments - Mayo Clinic

    carcinoma in situ, Male breast cancer, Endometrial cancer, Phyllodes tumor. Show more areas of focus for Oluwadamilola T. Oladeru, M.D., M.B.A.. Research.

  5. Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer - Mayo Clinic

    There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. ... - NOTE: Tumor lesions in ... situ of the cervix, ...

  6. Clinical trials - Oncology (Medical)

    ... in situ with or without Ta/T1 disease. Establishment of Preclinical Models from Patients with Gynecological Malignancies. Rochester, Minn., Scottsdale ...

  7. Clinical trials - Oncology (Medical)

    ... in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of ...

  8. A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma - Mayo Clinic

    ... in situ of the cervix or breast, or other non-invasive lesion), which is considered cured with minimal risk of recurrence within 3 years. Either of the ...

  9. Clinical trials - Oncology (Medical)

    ... in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of ...

  10. Sentinel node biopsy - Doctors & Departments - Mayo Clinic

    Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. ... situ, Recurrent ...